Bangalore: GlaxoSmithKline Biologicals , a division of global drug giant Glaxo, is in talks with the Hyderabad-based Biological E Ltd (BE) to purchase its vaccines division , people familiar with the discussions said.
This division produces and markets a range of paediatric and adult vaccines and has a sizeable market share in the Indian vaccine market . Officials from Glaxo Biologicials, which is based in Belgium, recently visited the Indian firm's manufacturing facility in Shameerpet near Hyderabad, people close to the development said.
Biological E managing director Dr Vijay Kumar Datla did not respond to an emailed questionnaire on the issue. A Glaxo spokesperson in Mumbai declined to comment.
BE, which has already invested around Rs 350 crore for its facilities, has three key divisions, biologics, pharma and public markets. Biologics makes paediatric and adult vaccines, while public markets is in charge of distributing all kinds of vaccines to the state and central govt and public health services.
The talks are believed to be at a preliminary stage. The Biological E's website says that it was the first private sector company to enter the vaccines market. Diphtheria and tetanus vaccines are some of its key products and this has given BE a significant share of the Indian vaccine market. Its pharma division manufactures solid dosage forms, liquid orals, syrups and active pharmaceutical ingredients catering to both local and international markets.
A pharma analyst said Glaxo had recently faced some constraints in supplying vaccines to its markets around the world from its plant in Nashik, Maharashtra. It would be interested in buying out companies with modern manufacturing facilities approved by international agencies like US FDA, said the analyst, who did not wish to be quoted because he is not authorised by his firm to speak. He also added that GSK Biologicals is globally huge in paediatric vaccines and BE's expertise in that segment would offer excellent synergies in terms of a strategic fit.
Glaxo was also believed to be interested in Shantha Biotech which was eventually sold to French drugmaker Sanofi's vaccine division for $ 780 million in 2009.
The Belgium-headquartered GSK Biologicals is one of the world's leading vaccine manufacturers and employs more than 1,000 research scientists. As per a previous company statement, in India, the division leads the vaccine market in terms of market share and also exports vaccines to both developed and developing markets.
1 comment:
I think this is one of the most important information for me. And i am glad reading your article. But should remark on few general things, The website style is perfect, the articles is really nice
Post a Comment